India Ocular Hypertension Treatment Market Size, Share, Growth Analysis Report, 2023 – 2028
India Ocular Hypertension Treatment Market (By Type: Intraocular Hypertension, Glaucoma); (Treatment Type: Drug Class- Latanoprost, Pilocarpine, Acetazolamide, Dorzolamide, Timolol; Surgery; Laser Therapy) (Route of Administration: Oral, Parenteral, Others) (Prescription mode: Prescription, OTC); (End User: Hospitals Homecare, Specialty Clinics); (Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy); (Region: Asia Pacific ( India).
Market Definition
A condition known as ocular hypertension is when the pressure inside the eye rises without impairing vision or harming the structure of the eye. It develops when fluid in the eye doesn't leave the eye at its normal pace, causing an accumulation that raises intraocular pressure. Ocular hypertension could be a precursor to glaucoma, an eye condition that, if left untreated, can eventually result in irreparable vision loss.
Report Preview
India Ocular Hypertension Treatment Market is projected to grow at a CAGR of 9% during the forecast period of 2023-2028, crossing US$ 250 Million by 2028
Around 11.2 million people aged 40 years and above in India have glaucoma but only 20 per cent of them are aware of it, experts said on the World Glaucoma Day on Tuesday. The numbers can be more as more than 70 per cent of cases go undetected.
In 2023 - 12 million people are affected accounting for 12.8 percent of the country’s blindness.
India Ocular Hypertension Treatment Market is Driven by the Rise in Prevalence of Ocular Hypertension:
Worldwide, population-based studies have shown varying rates of ocular hypertension (OHT), ranging from 1.1 to 13%. Two reports from India are based on population. According to the Vellore Eye Study (VES), OHT prevalence was 3.0% (95% CI: 2.0 - 4.0%).Thirteen This was observed by the Andhra Pradesh Eye Disease study (APEDS) to be 0.32% (95% CI: 0.10%-0.78%).
India Ocular Hypertension Treatment Market: Market Drivers
Increasing prevalence: Increasing prevalence of ocular diseases such as glaucoma and diabetic retinopathy.
Rising geriatric population: Rising geriatric population, which is more susceptible to eye disorders.
Growing awareness about the importance of regular eye check-ups.
Advances in pharmaceutical and surgical treatment options.
Restraints
High cost of advanced treatment options.
Lack of access to specialized healthcare in rural areas.
Limited awareness about ocular hypertension in certain demographics.
Challenges
Ensuring the availability of affordable treatment options.
Overcoming the shortage of trained ophthalmologists in the country.
Addressing the side effects associated with long-term use of ocular hypertension medications.
Opportunities
Increasing investments in healthcare infrastructure.
Development of cost-effective generic medications.
Growth in medical tourism due to affordable treatment options in India.
Dominance of Region:
India is emerging as a significant player in the global ocular hypertension treatment market due to its large population and increasing healthcare investments.
Market Growth Country:
India is expected to see substantial growth, driven by increasing awareness and improving access to healthcare services.
Ocular Hypertension Causes:
Overproduction of Aqueous Humor: Aqueous humor is the fluid that lies in between the cornea and lens of the eye. The ciliary body is the source of it. An increase in aqueous output may result in elevated intraocular pressure.
Insufficient Aqueous Drainage: At the iris-cornea intersection, a trabecular meshwork allows aqueous humor to escape. An rise in intraocular pressure may result from sluggish drainage through the trabecular meshwork.
Corticosteroids: Using steroid eye drops or tablets orally may raise intraocular pressure.
Eye Injury: Ocular hypertension may result from an eye injury.
Ocular Hypertension Treatment
For those with ocular hypertension, topical ocular hypotensive medications can help delay the onset of primary open-angle glaucoma. These are the drugs used to reduce intraocular pressure.
Latanoprost: An analog of prostaglandin. It decreases intraocular pressure by increasing the aqueous uveoscleral outflow.
Pilocarpine is a cholinergic medication. By encouraging the trabecular meshwork to open and boosting the aqueous outflow, it lowers the intraocular pressure.
Use Pilocarpine, Acetazolamide, and Dorzolamide to Treat Ocular Hypertension: They are inhibitors of the enzyme carbonic anhydrase. They lower the intraocular pressure by reducing the ciliary body's production of aqueous matter.
Timolol: This substance is a beta-blocker. It lowers the intraocular pressure by reducing the ciliary body's production of aqueous humor.
India Ocular Hypertension Treatment Market: Market Segmentation
By Treatment Type:
Drug Class; Latanoprost, Pilocarpine, Acetazolamide, Dorzolamide, Timolol
Surgery
Laser Therapy
Route of Administration:
Oral
Parenteral
Others.
Prescription Mode:
Prescription
OTC
End User:
Hospitals Homecare
Specialty Clinics
Distribution Channel:
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
India Ocular Hypertension Treatment Market: Fastest Growing Segmentation:
Pharmaceuticals are expected to be the fastest-growing segment due to the increasing preference for non-invasive treatment options.
Major Companies Operating In India Regions
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Lupin Limited.
Latest News & Recent Development News
In 2023, Sun Pharma acquired a smaller ophthalmic drug manufacturer to expand its product portfolio.
Cipla entered into a strategic partnership with a Japanese company to enhance its R&D capabilities.
In 2023, Lupin launched a new eye drop formulation for the treatment of ocular hypertension.
Pfizer introduced an advanced laser therapy device for eye treatments.
Report Highlights
The Indian ocular hypertension treatment market is expected to grow at a CAGR of 9% from 2023 to 2028.
Pharmaceuticals are the fastest-growing segment in the market.
Major companies like Sun Pharma and Cipla are expanding their product portfolios and R&D capabilities.
Increasing awareness and healthcare investments are driving market growth in India.
